

Special Issue

Discovery and Evaluation of Novel Adjuvants for Vaccine Formulations

Message from the Guest Editors

Vaccination has been a key strategy for the prevention and treatment of numerous pathologies worldwide. The development of vaccines incorporating only certain components of pathogens, such as the protein, sugar or capsid, has resulted in formulations capable of inducing immune responses of greater specificity, with fewer side effects. However, due to the lower immunogenicity of such components, adjuvants are required for the induction of sufficient immune responses. Adjuvants such as alum have been in clinical use for 100 years, but with the advancements in the understanding of the immune system and high throughput discovery methods for identifying potential candidates, a new generation of novel adjuvants with high efficacy and simultaneous safety are possible. This Special Issue will highlight aspects associated with novel vaccine adjuvants, through the stages of discovery, screening, evaluation, and incorporation as formulations.

Guest Editors

Prof. Dr. Imran Saleem

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK

Dr. Kan Kaneko

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK

Deadline for manuscript submissions

closed (31 May 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/33013

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).